• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Drug-Device Combinations

Portal Diabetes earns FDA breakthrough nod for implantable insulin pump

February 17, 2026 By Sean Whooley

Portal Diabetes Portal Pump implantable insulin pump

Portal Diabetes announced today that it received FDA breakthrough device designation for its implantable insulin pump system. The Westfield, Indiana–based company can now begin a Phase 1 study to evaluate its proprietary, temperature-stable insulin. It aims to deliver a functional cure for type 1 diabetes. Portal Diabetes developed its system, called the Portal Pump, to […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Regulatory/Compliance, Technology Tagged With: FDA, Portal Diabetes

Dexcom beats Street in Q4 on 13% sales growth

February 12, 2026 By Sean Whooley

Dexcom updated Logo

Dexcom (NSDQ:DXCM) shares ticked up after hours today on fourth-quarter results that came in ahead of the consensus forecast. Shares of DXCM rose 1% to $65.70 apiece in post-market trading today. The San Diego-based continuous glucose monitor (CGM) maker reported profits of $267.3 million. That equals 68¢ per share on sales of $1.259 billion for […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Dexcom

Embecta names CEO Kurdikar as new board chair, picks new lead independent director

February 11, 2026 By Sean Whooley

Embecta CEO Devdatt Dev Kurdikar headshot

Embecta (Nasdaq:EMBC) announced today that its board of directors elected the company’s CEO, Devdatt “Dev” Kurdikar, as chair. The Parsippany, New Jersey-based BD Diabetes spinoff also named Dr. Claire Pomeroy as lead independent director. Both appointments go into effect immediately. These changes follow the retirement of David Melcher, who previously served as non-executive chair of the […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Personnel Tagged With: embecta, Personnel Moves

LifeScan, i-SENS partner to launch CGM platform

February 11, 2026 By Sean Whooley

LifeScan OneTouch app

LifeScan announced today that it partnered with i-SENS to launch a continuous glucose monitoring (CGM) system. Malvern, Pennsylvania–based LifeScan develops the OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app. It aims to provide simplicity, accuracy and trust in diabetes management. i-SENS, a global in vitro diagnostics company, researches, develops and produces products leveraging advanced […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: i-SENS, lifescan

MannKind enrolls first patient in study of inhaled insulin for pediatric type 1 diabetes

February 9, 2026 By Sean Whooley

MannKind afrezza inhaled insulin in use

MannKind (Nasdaq:MNKD) announced today that it enrolled the first patient in the INHALE-1ST study of its Afrezza inhaled insulin. INHALE-1ST evaluates the initiation of Afrezza inhalation powder therapy shortly after type 1 diabetes diagnosis in pediatric patients. Afrezza (insulin human) inhalation powder is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: mannkind

Modular Medical hits validation milestone, targets commercial launch for insulin patch pump soon

February 6, 2026 By Sean Whooley

Modular Medical Pivot insulin patch pump

Modular Medical (Nasdaq:MODD) announced that it started the production of validation lots for its Pivot tubeless insulin patch pump. The lots include the next-generation Pivot pump’s disposable cartridge and infusion set. With the milestone, the San Diego-based company said it remains on track for a commercial launch in the first quarter of 2026, subject to […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Technology Tagged With: modularmedical

Insulet launches Omnipod 5, Omnipod Discover in the Middle East

February 5, 2026 By Sean Whooley

Insulet Omnipod 5 in Pool

Insulet (Nasdaq:PODD) announced today that it launched its Omnipod 5 and Omnipod Discover offerings in the Middle East. The company made its automated insulin delivery system available in Saudi Arabia, Kuwait, Qatar and the United Arab Emirates (UAE). Omnipod 5 became the world’s first available tubeless, wearable, automated insulin delivery system when it received FDA […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: Insulet

Embecta stock ticks up on Street-beating Q1

February 5, 2026 By Sean Whooley

BD Diabetes Spinoff Embecta

Embecta (Nasdaq:EMBC) shares got a boost today on first-quarter results that beat the consensus Wall Street forecast. Shares of EMBC rose 6.5% to $12.09 apiece in early-morning trading today. The Parsippany, New Jersey-based BD Diabetes spinoff reported profits of $44.1 million. That equals 74¢ per share on sales of $261.2 million for the three months ended […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: embecta

Beta Bionics receives FDA warning letter

February 5, 2026 By Sean Whooley

Beta Bionics iLet Bionic Pancreas (2024)

Beta Bionics (Nasdaq:BBNX) recently disclosed the receipt of a warning letter from the FDA following an inspection. An FDA inspection of the company’s Irvine, California, facility from June 9, 2025, through June 26, 2025, led to the warning letter. In the letter, the FDA outlined deficiencies in the automated insulin delivery system maker’s response letters […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance, Technology Tagged With: Beta Bionics, FDA

Dexcom adds enhanced smart meal logging feature to Stelo CGM

February 4, 2026 By Sean Whooley

Dexcom Stelo AI Smart Food Logging (1)

Dexcom (NSDQ:DXCM) announced today that it plans to launch an advanced AI-enabled enhancement to its Stelo over-the-counter CGM. The new enhancements to the continuous glucose monitor (CGM) aim to transform how users understand their glucose health. Dexcom said it hopes to help Stelo users achieve their long-term health goals through the updates. It plans to […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Interim pages omitted …
  • Page 374
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS